

Table of Contents.

Third quarter, July-September 2018	3
Year to date, January-September 2018.	3
Financial overview	3
CEO statement - Partnership in UAE progressing with start of local subsidiary	4
Significant events during the period.	6
Significant events after the end of the period	6
Comments on the financial results	7
Submission of interim report	12
Financial statements.	13
Consolidated statement of comprehensive income	13
Consolidated statement of financial position	14
Consolidated statement of changes in equity	16
Consolidated statement of cash flows	17
Parent company income statement	18
Parent company balance sheet.	19
Notes	21
About Brighter	23

Third quarter, July-September 2018.

- Capitalized expenditure for development work reached SEK 2,404 thousand (2,019)
- Operating income amounted to SEK 2,655 thousand (2,321)
- Operating result amounted to SEK -11,163 thousand (-4,890)
- Result before tax amounted to SEK -12,975 thousand (-7,478).
- Earnings per share, before dilution amounted to SEK -0.15 (-0.10).
- Earnings per share after dilution SEK -0.15 (SEK -0.10).

Year to date, January-September 2018.

- Capitalized expenditure for development work reached SEK 13,945 thousand (17,364)
- Operating income amounted to SEK 14,780 thousand (18,827)
- Operating result amounted to SEK -34,759 thousand (-13,291)
- Result before tax amounted to SEK -39,939 thousand (-20,971).
- Earnings per share, before dilution amounted to SEK -0.57 (-0.27).
- Earnings per share after dilution SEK -0.57 (-0.27).

Financial overview.

Jul-Sep 2018	Jul-Sep 2017	Jan-Sep 2018	Jan-Sep 2017	Jan-Dec 2017	Jan-Dec 2016
-11,163	-4,890	-34,759	-13,291	-19,946	-18,501
-958	-1,680	-2,177	-4,620	-2,897	-238
-12,975	-7,478	-39,939	-20,971	-27,292	-14,683
170,492	88,945	170,492	88,945	111,354	68,734
1.60	1.35	1.63	1.44	1.35	1.01
64%	88%	64%	88%	78%	76%
	2018 -11,163 -958 -12,975 170,492 1.60	2018 2017 -11,163 -4,890 -958 -1,680 -12,975 -7,478 170,492 88,945 1.60 1.35	2018 2017 2018 -11,163 -4,890 -34,759 -958 -1,680 -2,177 -12,975 -7,478 -39,939 170,492 88,945 170,492 1.60 1.35 1.63	2018 2017 2018 2017 -11,163 -4,890 -34,759 -13,291 -958 -1,680 -2,177 -4,620 -12,975 -7,478 -39,939 -20,971 170,492 88,945 170,492 88,945 1.60 1.35 1.63 1.44	2018 2017 2018 2017 2017 -11,163 -4,890 -34,759 -13,291 -19,946 -958 -1,680 -2,177 -4,620 -2,897 -12,975 -7,478 -39,939 -20,971 -27,292 170,492 88,945 170,492 88,945 111,354 1.60 1.35 1.63 1.44 1.35

For definitions, see note 24 in Brighter's 2017 Annual Report.



CEO statement - Partnership in UAE progressing with start of local subsidiary.

One of he highpoints of the third quarter was the launch of Brighter's joint venture with the AFAQ Group in Dubai, aimed at bringing Actiste into the United Arab Emirates. This is just the kind of international breakthrough we've been looking for, and we're now building up our organization there as a stepping stone to the broader Gulf region – one of the global hotspots in rising diabetes prevalence.

Back home in Sweden, our Board of Directors voted to initiate the process to apply for listing the company's shares on a regulated market. The listing will make it easier for institutional investors and international shareholders to trade in Brighter. It will also help to create the conditions for improved liquidity in the company's stock. This is an important step in realizing our global ambitions.

Brighter's team was given another boost in July when Jakarta-based Dr. Teddy Batanghari, co-founder of Kairos Healthcare and former CEO of Summit Healthcare, became Senior Advisor to Brighter. Teddy, former CEO of the prestigious Indonesian hospital Pandai Indah Kapuk for some 18 years, will be immensely helpful in advising Brighter with the introduction of Actiste in Southeast Asia. We're delighted to have him on board!

In terms of product development, we received news in August that the European Patent Office intends to grant Brighter's patent for the Artificial Intelligence-driven monitoring of medical devices. This is great news for our customers and our investors, as the patent will allow us to bring some new and valuable functionalities to Actiste in the future.

I want to thank Brighter's board, management and key personnel for exercising their warrants during the third quarter and contributing capital of more than SEK 29 million. In total, we raised SEK 37 million during the period, which will now allow us to invest the resources we need into the commercialization of Actiste in the United Arab Emirates. This capital injection has come at exactly the right moment for Brighter!

Finally, some great news on the digital front too. We received final approval during the quarter that the mobile applications and digital infrastructure behind Actiste have been CE certified! This follows extensive user testing on both iOS and Android that focused on both ease of use and technical support. I'm very pleased that our solution achieved a score equivalent to 92% of the maximum! A big thank you to all for the hard work from our digital team that made this possible.

Best wishes,

Truls Sjöstedt, Founder and CEO of Brighter AB.

Significant events during the period.

- The European Patent Office intends to grant Brighter's patent for Al-powered monitoring of medical devices.
- Brighter draws down the seventh tranche of SEK 5 million under the financing agreement with L1 Capital and issues additional free warrants to its shareholders.
- Dr. Teddy Batanghari, Kairos Healthcare's Co-Founder and former CEO of Summit Healthcare, becomes Senior Advisor to Brighter.
- Brighter and AFAQ initiate partnership to launch Actiste in the GCC and a corporation has been established in the UAE.
- Brighter's Board of Directors has decided to initiate the process to apply for listing its shares on a regulated market.
- Brighter has been named one of the Nordic's most promising growth companies 2018 and as such participated in the Serendipidy Challenge 2018 in Sweden.
- Brighter announces Actiste pricing.
- Brighter expands its communication with podcast.
- The Actiste companion applications and The Benefit Loop are now CE certified.
- Brighter strengthens its financing with SEK 2.9 million through exercise of warrants in series TO4.
- Brighter receives SEK 29 million from the company's management, board and key personnel through the subscription of shares relating to warrants in series 2014/2017 and 2015/2018.
- The number of shares in Brighter AB has increased. The total number of shares and votes has increased from 65,826,337 to 68,942,747.

Significant events after the end of the period.

- Brighter appoints Deputy Managing Director of the company's UAE subsidiary.
- Brighter receives SEK 0.8 million through exercise of warrants of serie TO3.
- The number of shares in Brighter AB has increased. The total number of shares and votes has increased from 68,942,747 to 73,959,426.

Comments on the financial results.

Financial results for July-September 2018.

Income

Other operating income amounted to SEK 251 thousand (SEK 302) for the third quarter. In 2018 this relates mainly to consultancy revenue from the associated company Camanio Care. In 2017 it is also comprised of the compensation received from the dispute with the subcontractor HotSwap concerning defective deliveries in development work from before 2015.

Operating result

Operating result for the third quarter 2018 amounted to SEK -11,163 thousand (-4,890). The main reason for the higher loss was an increase in external costs, mainly in external services that relate primarily to services for financial and legal services related to the raising of capital and commercialization activities, and services to build up sales, logistics and production for Actiste. External costs relating to development are reflected in revenue in the form of Capitalized production costs SEK 2,404 thousand (2,019) at the same amount, which means that they do not have any impact on operating result.

Staff costs amounted to SEK -2,958 thousand (-1,979). At the end of the period, the numbers of employees were 14 (13), of whom 6 (6) were women. Also a number of consultants work for Brighter and this has been recognized in other external costs.

Cash flow

At the beginning of the quarter, the company had cash of SEK 4,401 thousand (2,756), decreasing to SEK 4,197 thousand (6,472) by the end of period.

Cash flow from operating activities before change in working capital amounted to SEK - 31,873 thousand (-10,515). The change in working capital was SEK -20,244 thousand (-5,603). The change in working capital mainly relates to an increase in inventories, prepayments to Sanmina and a receivable relating to Camanio. Investments amounted to SEK 3,038 thousand (2,169) of which investment of SEK 2,538 thousand (1,603) in intangible assets and SEK 0 (543) thousand in property, plant and equipment mainly for production of Actise.

Financing of SEK 34,708 thousand (16,400) after costs was raised through new issues, warrants and loans during the period. L1 Capital contributed SEK 10 million of those and SEK 15 million was a short term loan from private investors.

Warrants are issued free to L1 Capital and to all of the shareholders of Brighter AB in parallel with the convertible notes. In the quarter new shares corresponding to SEK 2,893 thousand were subscribed by utilization of these warrants.

Total cash flow for the period amounted to SEK -204 thousand (3,716).

Financial results for January-September 2018.

Income

Other operating income amounted to SEK 835 thousand (SEK 1,463) for the first nine months of 2018. In 2018 this relates mainly to consultancy revenue from the associated company Camanio Care. In 2017 it is primarily comprised of the compensation received from the dispute with the subcontractor HotSwap concerning defective deliveries in development work from before 2015.

Operating result

Operating result for the first nine months of 2018 amounted to SEK -34,759 thousand (-13,291). The main reason for the higher loss was an increase in external costs, mainly in external services that relate primarily to services for the financial and legal services related to the raising of capital and commercialization activities, and services to build up sales, logistics and production for Actiste. External costs relating to development are reflected in revenue in the form of Capitalized production costs SEK 13,945 thousand (17,364) at the same amount, which means that they do not have any impact on operating result.

Staff costs amounted to SEK -9,119 thousand (-6,276). At the end of the period, the number of employees was 14 (13), of whom 6 (6) were women. Also a number of consultants work for Brighter and this has been recognized in other external costs.

Depreciation/amortization only relates to trademarks and material inventories. Other intangible assets, patents and development costs are not amortized before the asset is ready to be put into service. The value of the intangible assets is measured continuously, and it is intended that amortization start once Actiste is ready, in conjunction with approved CE marking.

Financial position

Capitalized expenditure for development work during the period amounted to SEK 13,945 (17,364) thousand, which almost exclusively relates to the development of Actiste. Capitalized expenditure totaled SEK 87,273 thousand (59,450).

Property, plant and equipment totaled SEK 5,933 thousand (1,711). The increase in the equipment is almost exclusively from investments in the production line, tools and other production related equipment for the production of Actiste. Depreciation of this equipment will start as soon as the production line is in use.

Inventories amounted to SEK 5,883 thousand (0) and relates to consumables held for sales together with Actiste devise.

Under "Other current receivables", SEK 59,683 thousand (12,288) there are pre-payments to Sanmina, for production of Actiste, of SEK 13.2 million (7.9). They also consist of a receivable on Camanio Care of SEK 11.5 million and a receivable related to the warrants 2014/2017 and 2015/2018 of SEK 29.4 million, which was received beginning of October.

As of September 30 the company had equity of SEK 109,490 thousand (78,377), an equity ratio of 64% (88%).

The company has no long-term liabilities. Current interest bearing from L1 amounted to a nominal value of SEK 5,600 thousand. This liability is reported at its amortized cost at SEK 4,825 thousand as of September 30, 2018.

Cash flow

At the beginning of the year, the company had cash of SEK 10,017 thousand (1,733), decreasing to SEK 4,197 thousand (6,472) by the end of period.

Cash flow from operating activities before change in working capital amounted to SEK - 59,359 thousand (-27,552). The change in working capital was SEK -23,965 thousand (-13,552). The change in working capital mainly relates to an increase in inventories, prepayments to Sanmina and a receivable relating to Camanio Care. Investments amounted to SEK 16,774 thousand (14,109), of which investment of SEK 14,937 thousand (16,123) in intangible assets, and SEK 1,299 thousand (1,514) in property, plant and equipment mainly for production of Actiste.

Financing of SEK 70,313 thousand (46,400) after costs was raised through new issues, warrants and loans during the period. L1 Capital contributed SEK 25 million of those and SEK 42 million was a short term loan from private investors. The company has a financing agreement with L1 for SEK 100 million, of which SEK 85 million has been utilized as of September 30, 2018. Financing through L1 Capital has been executed through current issues of convertible notes and at September 30 2018, the counterparty had used the opportunity to convert the corresponding SEK 79.4 million in nominal value of issued convertible notes. Warrants are issued free to L1 Capital and to all of the shareholders of Brighter AB in parallel with the utilization of convertible notes. During the period new shares corresponding to SEK 4,449 thousand were subscribed by utilization of these warrants. If all of the warrants within the framework of this agreement are issued and utilized to subscribe to new shares, this will add around a further SEK 100 million. For further information about the agreement with L1 Capital, see the company website and Note 21 in Brighter's 2017 Annual Report.

Total cash flow for the period amounted to SEK -5,819 thousand (4,739).

Sales, production and CE mark.

Sales work is continuing in a positive vein both in Sweden and globally. The sales and business target aimed at expanding into markets with strong needs and the ideal conditions for implementing digitalized treatment and monitoring systems continues. As such the partner-ship between Brighter and AFAQ Group L.L.C. is certainly one of Brighters more promising market breakthroughs lately. In July Brighter entered into a partnership to establish a company based in the United Arab Emirates and introduce Actiste ® Diabetes Management as a Service into the Gulf Co-operation Council (G.C.C.) region. AFAQ Group is committed to the success of Brighter in the Arab region. The market is vast and increasing. International Diabetes Federation predicts that the number of diabetics in the region will increase by 100% 2017-2045, making it one of the world's fastest growing regions for diabetes.

The work by Sanmina in preparations for producing Actiste is progressing according to plan. The CE marking process continues and involves a complex process that consists of multiple steps, including product, production and user tests, as well as reporting, verification and validations, which are handled by external certification partners. Technical files have been

handed to the certification partners, however further questions may occur, as we await the final approval.

Future liquidity position.

The commercialization of Actiste, with an ambitious plan for development and growth, requires the company to have sufficient working capital to be able to finance both capital commitments in respect of future deliveries, inventory as well as the production facility. Financing of the business is a very important part of the company's growth strategy, and the company's management and Board are working continuously on financing issues.

The additional contracted financing volume from L1 Capital, the cash received from warrants and other temporary loan financing, in combination with the liquidity as at September 30 2018 is not sufficient to finance the operations based on the current business plan and strategic direction decided upon. The Board and management therefore estimate that in 2018, the company will need to secure additional funding to be able to carry out operations based on the strategic direction that has been decided.

Upon submission of this report, the company has not yet secured all funding. However, the Board and management estimate that the company's ongoing financing activities, combined with the additional liquidity that conversions of outstanding warrants will render, will likely finance the business for at least 12 months ahead.

Risks and uncertainty.

The principal risks and sources of uncertainty for Brighter include, albeit not exclusively, financial risks, such as the future earnings trend, financing, liquidity and currency and credit risks. In addition to market and commercialization risks, there are also risks associated with Brighter's operations, such as dependencies of suppliers and key personnel, obtaining necessary approval from authorities, product development, patents and intellectual property rights and product responsibility. Further information on the Company's risk exposure can be found in Note 3 of Brighter's 2017 Annual Report.

Shareholders.

At September 30 2018, Brighter AB had approximately 6,200 shareholders, of whom the four largest represented approximately 30.7% of the capital and votes. The total number of shares September 30th, 2018 amounts to 67,653,161. The largest shareholders were Försäkringsbolaget Avanza Pension (13.5%), Truls Sjöstedt (8.9%), Ålandsbanken AB, W8IMY (3.0%) and Ålandsbanken on behalf of the owner (5.3%).

Warrants have been issued on several occasions. The subsidiary Brighter One AB is the holder of the warrants, to be allotted to employees, the Board, the CEO and management. Brighter One is also the holder of the TO3-series and TO4-series to be allotted the shareholders and L1 Capital as part of the L1 Capital agreement. For further information on the L1 Capital agreement se Note 21 of Brighter's 2017 Annual Report. During the first quarter of 2018 111,770 warrants of TO4-series were converted into shares and in the second quarter, 221,111 warrants of TO3-series were converted. In the third quarter 481,353 warrants of TO4-series were converted as well as 2,541,177 warrants of series 2014/2017 and

2015/2018 which after recalculation according to the warrant terms resulted in 3,383,137 new shares. For further description of all the programs please see the Company's website and the summary in Note 19 of Brighter's 2017 Annual Report.

Camanio Care.

As of September 30, 2018 Brighter owns 4,126,236 shares in Camanio Care, which is an ownership of 24.75%. Camanio Care is listed at Aktietorget. The share price at the end of September 2018 was SEK1.75 per share, which gives a market value of Brighter's holding at SEK 7.2 million. The acquisition value of the shares in the Parent company is SEK 9.4 million and a write-of of the difference, SEK 2.1 million is thus applied to the quarterly accounts of the Parent Company as of September 30, 2018.

In the first quarter 2018 Brighter signed a guarantee of maximum SEK 800 thousand on behalf of Camanio Care for funding of customer contracts financed by Svea ekonomi. The guarantee will last a maximum of 12 months. Brighter has also lent SEK 12.0 million to Camanio Care. The financing lent is not a liquidity strain on Brighter, since it is fully supplied to Brighter by external parties. Brighters role in this is solely a guarantor for repayment and Brighter has in its turn security in assets in Camanio.

Camanio Care reported a loss of SEK -4,210 thousand for the third quartet of 2018. The reported loss was SEK -12,712 thousand for January to September 2018.



Submission of interim report.

Stockholm, November 15, 2018. Brighter AB (publ).

The Board of Directors and the CEO certify that the interim report for the period January–September 2018 provides a fair view of the operations, financial position and results of the Parent Company and Group, and describes material risks and uncertainties facing the Parent Company and the companies included in the Group.

Barbro Fridén Truls Sjöstedt Jan Stålemark Chairperson of the Board CEO Board Member

Afsaneh Ghatan Bauer Lars Flening Catarina Ihre Board Member Board Member Board Member

Sara Murby Forste Board Member

Financial calendar.

Interim Report Oct-Dec 2018: 27/2/2019

Annual Report 2018: 27/3/2019

Annual General Meeting: 9/5/2019

Interim Report Jan-Mar 2019: 22/5/2019
Interim Report Apr-Jun 2019: 28/8/2019
Interim Report Jul-Sept 2019: 11/20/2019

Audit.

This interim report, and the financials in it, has not been audited.

Financial statements.

Consolidated statement of comprehensive income.

Amounts in SEK thousand	Note	Jul-Sep 2018	Jul-Sep 2017	Jan-Sep 2018	Jan-Sep 2017
Capitalized production costs		2,404	2,019	13,945	17,364
Other operating income		251	302	835	1,463
Total operating income		2,655	2,321	14,780	18,827
Raw materials and consumables		0	0	0	0
Other external costs		-10,681	-5,181	-40,075	-25,683
Staff costs		-2,958	-1,979	-9,119	-6,276
Depreciation/amortization of tangible and intangible assets		-37	-51	-131	-150
Other operating costs		-142	0	-214	-9
Total operating costs		-13,818	-7,211	-49,540	-32,118
Operating result		-11,163	-4,890	-34,759	-13,291
Other financial income		1,022	0	1,022	3
Financial expenses		-1,980	-1,680	-3,199	-4,622
Net financial items		-958	-1,680	-2,177	-4,620
Income from shares in associated companies after tax		-854	-908	-3,002	-3,061
Result before income tax		-12,975	-7,478	-39,939	-20,971
Income tax		0	0	0	0
Result for the period		-12,975	-7,478	-39,939	-20,971
Other comprehensive income:					
Translation differences on foreign operations		7	0	7	0
Total comprehensive income for the period		-12,968	-7,478	-39,932	-20,971
Attributable to the parent company's shareholders		-12,968	-7,478	-39,932	-20,971
Amounts in SEK		Jul-Sep 2018	Jul-Sep 2017	Jan-Sep 2018	Jan-Sep 2017
Earnings per share before dilution	3	-0.15	-0.10	-0.57	-0.27
Earnings per share after dilution	3	-0.15	-0.10	-0.57	-0.27

Consolidated statement of financial position.

Amounts in SEK thousand		Sep 30 2018	Sep 30 2017	Dec 31 2017
Capitalized expenditure for development work		87,273	59,450	73,327
Concessions, patents, licenses, trademarks and similar rights		4,431	3,107	3,467
Total intangible assets		91,704	62,556	76,794
Equipment, tools and installations		107	223	211
Construction in progress		5,826	1,488	4,527
Total property, plant and equipment		5,933	1,711	4,738
Shares in associated companies and jointly controlled companies		0	3,289	2,965
Other long-term securities		964	464	464
Other long-term receivables		125	273	0
Total financial assets		1,089	4,027	3,429
Total fixed assets		98,726	68,295	84,961
Inventories		5,883	0	0
Total inventories		5,883	0	0
Accounts receivable	4	721	37	757
Other current receivables	5	60,133	12,288	15,174
Prepayments and accrued income		831	1,852	445
Total current receivables		61,686	14,178	16,376
Cash and cash equivalents	4,5	4,197	6,472	10,017
Total current assets		71,765	20,650	26,393
TOTAL ASSETS		170,492	88,945	111,354

Consolidated statement of financial position cont.

Amounts in SEK thousand	Note	Sep 30 2018	Sep 30 2017	Dec 31 2017
Share capital		3,660	3,121	3,248
Other contributed equity		232,692	177,315	171,071
Retained earnings		-126,862	-102,059	-86,930
Total Equity		109,490	78,377	87,389
Total equity attributable to the parent company's shareholders		109,490	78,377	87,389
Accounts payable	4	9,595	7,725	10,824
Convertible loans	4,5	4,825	1,064	8,437
Other current liabilities	4	42,550	330	2,102
Accruals and deferred income		4,032	1,449	2,602
Total current liabilities		61,002	10,568	23,965
TOTAL EQUITY AND LIABILITIES		170,492	88,945	111,354

Consolidated statement of changes in equity.

Amounts in SEK thousand Balance at start of year, January 1, 2017 Result for the year Other comprehensive income	Share Capital 2,601	Other contributed equity 109,580	Result carried forward (including result for the period) -59,638 -27,292	Total equity 52,543 -27,292
Total comprehensive income			-27,292	-27,292
<u>Transactions with shareholders</u> The value of conversion rights for convertible debt instruments		9,397		9,397
Conversion of convertible debt instruments	501	42,564		43,065
New issues, cash and offsetting	146	11,582		11,728
Issue costs		-2,052		-2,052
Total transactions with shareholders	647	61,491	0	62,138
Balance at end of quarter, December 31, 2017	3,248	171,071	-86,930	87,389
Balance at start of year, January 1, 2018	3,248	171,071	-86,930	87,389
Result for the period			-39,939	-39,939
Translation differences on foreign operations			7	7
Total comprehensive income			-39,932	-39,932
Transactions with shareholders				
The value of conversion rights for convertible debt instruments		3,908		3,908
Conversion of convertible debt instruments	202	25,276		25,478
New issues, cash and offsetting	210	33,608		33,818
Issue costs		-1,171		-1,171
Total transactions with shareholders	412	61,621	0	62,033
Balance at end of year, September 30, 2018	3,660	232,692	-126,862	109,490

Consolidated statement of cash flows.

Amounts in SEK thousand	Note	Jul-Sep 2018	Jul-Sep 2017	Jan-Sep 2018	Jan-Sep 2017
Operating result		-11,163	-4,890	-34,759	-13,291
Adjustment for items not included in the cash flow		1,263	51	1,107	150
Interest received		0	0	0	2
Interest paid		-1,730	-72	-1,742	-861
Income tax paid		0	0	0	0
Cash flow from operating activities before change in working capital		-11,629	-4,911	-35,394	-14,000
Increase/decrease in inventories		-4,740	0	-5,883	0
Increase/decrease in operating receivables		-18,465	-3,229	-16,821	-9,640
Increase/decrease in operating liabilities		2,961	-2,375	-1,261	-3,913
Total change in working capital		-20,244	-5,603	-23,965	-13,552
Cash flow from operating activities		-31,873	-10,515	-59,359	-27,552
Investments in intangible assets		-2,538	-1,603	-14,937	-16,123
Investments in property, plant and equipment		0	-543	-1,299	-1,514
Investment in financial assets		-500	-23	-538	3,527
Cash flow from investing activities		-3,038	-2,169	-16,774	-14,109
Loans raised		32,000	10,000	67,000	40,000
Cost of capital for convertible loans		-150	0	-450	0
New share issues and warrants		2,893	6,400	4,485	6,400
New share issue costs		-35	0	-721	0
Cash flow from financing activities		34,708	16,400	70,313	46,400
Cash flow for the period		-204	3,716	-5,819	4,739
Opening cash and cash equivalents		4,401	2,756	10,017	1,733
Closing cash and cash equivalents		4,197	6,472	4,197	6,472

Parent company income statement.

Amounts in SEK thousand	Note	Jul-Sep 2018	Jul-Sep 2017	Jan-Sep 2018	Jan-Sep 2017
Capitalized production costs		2,404	2,019	13,945	17,364
Other operating income		209	302	793	1,463
Total operating income		2,613	2,321	14,738	18,827
Raw materials and consumables		0	0	0	0
Other external costs		-9,802	-5,181	-39,179	-25,660
Staff costs		-2,937	-1,979	-9,097	-6,276
Depreciation/amortization of tangible and intangible assets		-37	-51	-131	-150
Other operating costs		-126	0	-214	-9
Total operating costs		-12,902	-7,211	-48,621	-32,095
Operating result		-10,289	-4,890	-33,883	-13,268
Other interest income and similar income		2,755	0	1,022	3
Interest expenses and similar expenses		-1,980	-772	-5,374	-1,561
Total result from financial items		775	-772	-4,353	-1,558
Result after financial items		-9,515	-5,662	-38,235	-14,826
Appropriations		0	0	0	0
Tax on result for the period		0	0	0	0
Result for the period		-9,515	-5,662	-38,235	-14,826

Parent company balance sheet.

Amounts in SEK thousand	Note	Sep 30 2018	Sep 30 2017	Dec 31 2017
Capitalized expenditure for development work		87,273	59,450	73,327
Concessions, patents, licenses, trademarks and similar rights		4,431	3,107	3,467
Total intangible assets		91,704	62,556	76,794
Equipment, tools and installations		107	223	211
Construction in progress		5,826	1,488	4,527
Total property, plant and equipment		5,933	1,711	4 738
Shares in Group companies		50	50	50
Shares in associated companies		7,221	11,857	9,396
Other long-term securities		964	464	464
Other long-term receivables		0	273	0
Total financial assets		8,235	12,645	9,911
Total fixed assets		105,873	76,912	91,443
Inventories		5,883	0	0
Total inventories		5,883	0	0
Accounts receivable		721	37	757
Other receivables		61,095	12,288	15,284
Prepayments and accrued income		832	1,852	407
Total current receivables		62,648	14,178	16,448
Cash at bank and in hand		4,226	6,472	9,825
Total current assets		72,757	20,650	26,273
TOTAL ASSETS		178,629	97,562	117,716

Parent company balance sheet cont.

Amounts in SEK thousand	Note	Sep 30 2018	Sep 30 2017	Dec 31 2017
Share capital		3,660	3,121	3,248
Development expenses fund		68,445	44,830	51,560
Restricted equity		72,105	47,951	54,808
Share premium		231,918	154,290	171,071
Result carried forward		-148,239	-102,981	-109,288
Result for the period		-38,235	-14,826	-22,841
Unrestricted equity		45,443	36,483	38,942
Total equity		117,548	84,434	93,750
Accounts payable		9,596	7,725	10,806
Convertible loans		4,825	1,064	8,437
Other liabilities		42,627	2,890	2,121
Accruals and deferred income		4,033	1,449	2,603
Total current liabilities		61,081	13,128	23,967
TOTAL EQUITY AND LIABILITIES		178,629	97,562	117,716

Notes

Note 1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report. Significant accounting and valuation principles are detailed on pages 32-44 of Brighter's 2017 Annual Report. Important estimates and assumptions for accounting purposes can be found in Brighter's 2017 Annual Report in Note 4.

Note 2 General information

Brighter AB (publ.) corporate registration number 556736-8591 is a Parent Company registered in Sweden, with its registered office in Stockholm, at Norgegatan 2, SE-164 32 Kista, Sweden. The business is located at this address. Brighter develops technical and digital medical devices with a primary area of application in the treatment of diabetes. Brighter AB (publ) has a wholly owned subsidiary, Brighter One AB, the only function of which is to hold options as part of the external financing of the Company and as part of the incentive scheme. The Group has an associated company, Camanio Care, listed on Aktietorget. Brighter's share of ownership was 24,75% as of September 30th 2018.

Brighter AB is listed on NASDAQ First North/BRIG. The Brighter Certified Adviser on Nasdaq First North is Eminova Fondkommission AB.

The figures in the report are reported in SEK thousand unless otherwise stated.

Note 3 Earnings per share

SEK thousand	Jul-Sep 2018	Jul-Sep 2017	Jan-Sep 2018	Jan-Sep 2017
Result for the period attributable 100% to the Parent Company's shareholders	-9,964	-5,662	-38,686	-14,835
Number of shares at end of period before dilution	68,942,747	60,675,990	68,942,747	60,675,990
Number of shares at end of period after dilution	95,071,205	88,950,880	95,071,205	88,950,880
Weighted average number of shares before dilution	68,597,164	58,065,513	67,130,685	54,313,342
Earnings per share as a weighted average before dilution	-0.15	-0.10	-0.58	-0.27
Earnings per share (SEK) as a weighted average after dilution	-0.15	-0.10	-0.58	-0.27

Note 4 Financial instruments

SEK thousand	Sep 30 2018	Sep 30 2017	Dec 31 2017
Loan and accounts receivable:			
Accounts receivable and other receivables, excluding interim claims	60,854	12,325	15,931
Cash and cash equivalents	4,197	6,472	10,017
Total	65,051	18,797	25,948
Other financial liabilities:			
Convertible bonds	4,825	1,064	8,437
Other interest-bearing debt	42,000	0	0
Accounts payable and other liabilities, excluding non-financial liabilities	10,145	8,055	12,926
Total	56,970	9,119	21,363

Note 5 Borrowing and net liabilities

SEK thousand	Sep 30 2018	Sep 30 2017	Dec 31 2017
Short-term			
Liabilities relating to interest-bearing debt or convertible bonds	46,825	1,064	8,437
Total borrowing	46,825	1,064	8,437
Cash and cash equivalents	4,197	6,472	10,017
Net debt interest-bearing liabilities	42,634	-5,408	-1,580
Equity	109,041	78,377	87,389
Debt to equity ratio	39.1%	-6.9%	-1.8%

Note 6 Transactions with affiliated parties

Transactions with affiliated parties in the form of remuneration, in addition to the Board fee, were carried out with the following Board members in the first quarter of 2018. Lars Flening received a fee of SEK 20,000 for consultancy services. There were no transactions with affiliated parties in the second or third quarter. The amount is exclusive of VAT. All transactions are carried out on a commercial basis.

About Brighter.

Brighter develops health-tech solutions that simplify the flow of relevant and reliable treatment data between patients, their loved ones, and their care providers. With this data-driven global approach, our goal is a higher quality of life and better health outcomes for people living with a disease around the world.

Brighter is currently focused on diabetes care with our mobile-connected solution Actiste®. However, in the future we envision our solutions being used to assist in various healthcare scenarios, including the treatment of other chronic conditions.

The key to our solutions is a service for remote-monitoring and treatment that links the digital and physical collection of healthcare data (with the consent of the user). We call this The Benefit Loop®: an intellectual property platform that can be applied within a variety of clinical settings to create smart solutions for remotely monitoring and treating diseases.

Targeting diabetes.

Diabetes is a chronic disease that causes blood glucose to rise to unhealthy levels, either due to insufficient production of insulin by the pancreas, or due to the body's resistance to insulin produced. Left untreated, diabetes can cause a wide range of serious health complications.

The American Diabetes Foundation has calculated that diabetes affects some 370 million adults worldwide, a number that is expected to rise to 422 million by 2030 (almost 10% of the adult population). In addition to the personal suffering it causes, diabetes represents a massive burden on healthcare systems, many of which are already strained by ageing populations and a rise in the incidence of other chronic conditions too. In a 2016 study (published in The Lancet) by Imperial College London, Harvard University, the World Health Organization and some 500 researchers across the world, the global cost of treating diabetes was determined to be USD 825 billion per year. This calculation did not include the cost of work days lost due to diabetes.

Diabetics, their families, healthcare institutions, insurance companies, doctors and nurses all need a better way to administer and monitor diabetes treatment; a way that makes life easier for the people and families affected by diabetes, while also easing the burden on healthcare systems and care providers.

This is where Brighter comes in with our solution Actiste.

The diabetes solution - Actiste.

Actiste is a diabetes treatment and monitoring solution that gives diabetics greater control over their condition, and provides healthcare providers with a clearer picture of a patient's health. Diabetics can use the Actiste device to record their blood sugar values, track meal information, administer insulin, and share their treatment data over-the-air with caregivers (such as family members, nurses and doctors).

By establishing a continuous flow of valid data between diabetics and their caregivers, Actiste improves patient adherence, eases concern among family members, allows doctors to quickly change treatment plans, and makes more efficient use of limited healthcare resources. By providing a clear and continuous picture of a patient's health, Actiste can help to reduce the often severe long-term physical effects of diabetes, which in turn reduces treatment costs for healthcare systems.

Actiste is also the world's first mobile-connected solution to combine the three essential components of daily diabetes care – a blood glucose meter, a lancet and an injection device – in a single device.

This simplifies daily life with diabetes by reducing the average number of treatment steps from 27 to 9 (a 67% reduction). The Actiste customer also has essential equipment (such as test strips, needles, lancets, etc.) automatically re-supplied when they begin to run low. This is another way in which Actiste helps to reduce the burden on healthcare systems.

The Benefit Loop®.

The Benefit Loop is Brighter's cloud-based service that processes, analyzes and returns health data in the treatment chain from various connected tools and apps. It has been developed to package and visualize relevant information, and send feedback to the user, in a smart and user-friendly way. The Benefit Loop is a key part of Brighter's vision of promoting behavioral change throughout the healthcare ecosystem. This means not only developing smart assistive devices, but also becoming a leading company in mobile health and data-driven healthcare.

Market focus and target groups.

Brighter's products and solutions are targeted at a range of groups:

- Consumers and patients
- Mobile network operators
- Payers: healthcare providers, governments/authorities, insurance companies, consumers, companies/employers
- Clinical Research Organizations (CROs)
- Pharmaceutical companies
- R&D organizations, authorities, and academic bodies

Future business opportunities.

Brighter is an entrepreneurial tech-based company that initializes and develops projects for value creation mainly in health-tech. The listed company Camanio Care – in which Brighter is a major shareholder – is one of our projects. Actiste is our main project, initially targeting diabetes, but with the potential to target several other chronic diseases. The health data generated through Actiste can also provide a base for further business opportunities in clinical research and similar areas.

For further information, please contact:

Truls Sjöstedt, CEO Ann Zetterberg, CFO Phone: +46 709 73 46 00 Phone: +46 708 37 21 23

This information is such information, as Brighter AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact persons for publication on November 15, 2018 at 08:45 CET.

